Medical articles today

/* 728x15, */

Syngo DynaCT Cardiac From Siemens: 3D Images For Cardiovascular Imaging

At the ESC (European Society of Cardiology) Congress 2009, Siemens will be demonstrating a new cardiac application for the syngo DynaCT Cardiac imaging application. During transfemoral aortic valve replacement, a heart valve prosthesis gets implanted via peripheral artery access. To position aortic valve prostheses accurately, the cardiologist must have very precise knowledge of the individual anatomy of the patient's aorta. That's where syngo DynaCT Cardiac comes in: During the intervention, it generates CT-like cross-sectional images on an angiographic C-arm system and offers 3D reconstruction of the aortic root. These 3D images can be overlaid on actual fluoroscopic images and provide a kind of three-dimensional roadmap for the examiner.

Siemens Exhibits Innovative Solutions For Cardiovascular Medicine At ESC 2009

Siemens Healthcare exhibits its innovations for cardiology at the Congress of the European Society of Cardiology (ESC) 2009. In addition to the latest imaging systems, this also includes laboratory diagnostics and clinical IT systems for patient management. During this year's event, Siemens will be offering visitors to the congress an extensive theoretical and practical training program on new diagnostic and therapeutic techniques. The great progress made in medicine during the past few decades has reduced the death rate for cardiac diseases considerably. At the same time, the number of patients with chronic heart diseases such as cardiac insufficiency has been rising, thus increasing healthcare costs.

/* 468x60, */

For Heart Patients Undergoing Angioplasty, Double Doses Of Clopidogrel Better Than Standard Doses

A landmark international study led by McMaster University researchers found high doses of the blood thinner clopidogrel ( Plavix ) significantly reduce complications in heart patients undergoing angioplasty to clear blocked arteries. Angioplasty, also known as percutaneous coronary intervention (PCI), carries with it the risk of a heart attack and stent thrombosis, the formation of life-threatening blood clots inside stents that prop open narrowed arteries. An international group of researchers from 39 countries found patients undergoing angioplasty benefited from a more aggressive antiplatelet regimen in which they were given double the standard dose for about a week.

Reduction In Cardiovascular Death Shown For The First Time With New Oral Antiplatelet Agent Ticagrelor

The presentation of the PLATO (A Study of Platelet Inhibition and Patient Outcomes), showed that ticagrelor (Brilinta® ) reduced the rate of cardiovascular (CV) events (CV death, myocardial infarction or stroke ) from 11.7% to 9.8% compared clopidogrel ( Plavix ® ) XX% (p<0.001, RRR = 16%), without an increase in major bleeding. This efficacy endpoint was driven by a statistically significant reduction in both CV death and myocardial infarction (MI) with no difference in stroke. Ticagrelor is the first antiplatelet agent to demonstrate a reduction in CV death across all major acute coronary syndromes (ACS) patient types. For every 1, 000 patients admitted to the hospital because of an ACS event, use of ticagrelor instead of clopidogrel, for up to one year, led to 14 fewer deaths, or 11 fewer MI's, or 8 fewer cases of stent thrombosis, without an increase in major bleeds.

Long-Term Anticoagulant Therapy In Atrial Fibrillation: Dabigatran Vs. Warfarin

The anticoagulant dabigatran is more effective than warfarin in the prevention of stroke in patients with atrial fibrillation, according to results from the RE-LY study (Randomized Evaluation of Long-term anticoagulant therapY). "Although researchers have been looking for a replacement for warfarin for several decades, nothing has been successful as an oral blood thinner, " says Professor Stuart Connolly, Director of the Division of Cardiology at McMaster University, Canada, and one of the leading investigators of the study. The RE-LY study compared two doses of dabigatran with the current standard therapy, warfarin, in 18, 113 patients with atrial fibrillation at increased risk of stroke.

/* 468x60, */

Healthy Eating And Associated Weight Loss Improves Cardiac Risk Factors

Cardiologist Philip Ades, M.D., not only counsels his cardiac rehabilitation patients to eat healthier food, he shows them how. The author of the "EatingWell for a Healthy Heart Cookbook" (Countryman Press, 2008), Ades' research focuses on cardiac rehabilitation, treatment of obesity, hypertension, and management of high cholesterol. The director of cardiac rehabilitation and preventive cardiology at the University of Vermont College of Medicine, Ades published a study in the May 2009 issue of the journal Circulation that showed weight loss achieved through regular exercise and mild caloric restriction improves insulin resistance and improves a host of other cardiac risk factors, such as blood pressure, cholesterol level, clotting measures and measures of inflammation.

Rocket: [100]
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy